{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:53:56Z","timestamp":1791219236088,"version":"4.1.0"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.ejca.2018.11.021","type":"journal-article","created":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T13:06:13Z","timestamp":1544706373000},"page":"93-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Development of mild drug-induced sclerosing cholangitis after discontinuation of nivolumab"],"prefix":"10.1016","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0203-973X","authenticated-orcid":false,"given":"Shoko","family":"Noda-Narita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suguru","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kousuke","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousuke","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Koike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3658-4442","authenticated-orcid":false,"given":"Hidenori","family":"Kage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahide","family":"Nagase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2018.11.021_bib1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2018.11.021_bib2","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/annonc\/mdw649","article-title":"Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury","volume":"28","author":"Gelsomino","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2018.11.021_bib3","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10637-017-0453-0","article-title":"Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer","volume":"35","author":"Kawakami","year":"2017","journal-title":"Invest N Drugs"},{"key":"10.1016\/j.ejca.2018.11.021_bib4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00262-017-2062-3","article-title":"Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell ling cancer: a case report","volume":"67","author":"Kashima","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ejca.2018.11.021_bib5","doi-asserted-by":"crossref","first-page":"E259","DOI":"10.1055\/a-0640-2392","article-title":"Peroral cholangioscopy of nivolumab-related (induced) ulcerative cholangitis in a patient with non-small cell lung cancer","volume":"50","author":"Kuraoka","year":"2018","journal-title":"Endoscopy"},{"key":"10.1016\/j.ejca.2018.11.021_bib6","article-title":"Anti-programmed cell death-1 immunotherapy-related secondary sclerosing cholangitis","author":"Ogawa","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ejca.2018.11.021_bib7","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1016\/j.jtho.2017.10.007","article-title":"Late-onset cholecystitis with cholangitis after avelumab treatment in non-small cell lung cancer","volume":"13","author":"Cho","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2018.11.021_bib8","series-title":"Sciff's disease of the liver","first-page":"523","article-title":"Primary sclerasing cholangitis","author":"Vierling","year":"2017"},{"key":"10.1016\/j.ejca.2018.11.021_bib9","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/s00534-012-0521-y","article-title":"Clinical diagnostic criteria of IgG4-related sclerasing cholangitis 2012","volume":"19","author":"Ohara","year":"2012","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"10.1016\/j.ejca.2018.11.021_bib10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0960-7404(02)00032-4","article-title":"Hepatic artery chemotherapy for colorectal liver metastases: technical considerations and review of clinical trials","volume":"11","author":"Slitzki","year":"2002","journal-title":"Surg Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.ejca.2018.11.021_bib11","doi-asserted-by":"crossref","first-page":"E153","DOI":"10.1055\/s-0029-1214707","article-title":"Secondary sclerosisng cholangitis after chemotherapy with bevacizumab and paclitaxel","author":"von Figura","year":"2009","journal-title":"Endoscopy"},{"key":"10.1016\/j.ejca.2018.11.021_bib12","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1007\/s10620-015-3914-3","article-title":"Docetaxel induced sclerosing cholangitis","volume":"60","author":"Horsley-Silva","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.ejca.2018.11.021_bib13","first-page":"888","article-title":"A case of secondary sclerosing cholangitis caused by chemotherapy with nab-paclitaxel. [in Japanese]","volume":"112","author":"Matsuo","year":"2015","journal-title":"Nihon Shokakibyo Gakkai Zasshi"},{"key":"10.1016\/j.ejca.2018.11.021_bib14","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immune correlates","volume":"28","author":"Brahamer","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918315193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918315193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T14:11:50Z","timestamp":1605622310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804918315193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":14,"alternative-id":["S0959804918315193"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.11.021","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of mild drug-induced sclerosing cholangitis after discontinuation of nivolumab","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.11.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}